International Journal of Cancer Management

Published by: Kowsar

Basal Cell Carcinoma Risk and TP53 Arg72Pro Polymorphism: An Algerian Population Study

Rym Abderrahmane 1 , Khedidja Benseddik 2 , * , Lotfi Louhibi 1 , Fatima Zohra Moghtit 1 , Amina Boubekeur 1 , Abdellah Boudjema 1 , Fouzia Benrrahal 3 and Nadhira Saidi-Mehtar 1
Authors Information
1 Laboratoire de Genetique Moleculaire et Cellulaire, Departement de Genetique Moleculaire Appliquee, Faculte des sciences de la nature et de la vie, Universite des Sciences et de la Technologie d’Oran-Mohamed Boudiaf-USTO MB-, BP 1505 El M’naouer 31000, Oran, Algeria
2 Laboratoire de Genie Biologique des Cancers, Faculte de medecine, Universite de Bejaia, Bejaia, Algeria
3 Centre Hospitalier d'Oran, 76, Bd Dr Benzardjeb, Plateau, Oran, Algeria
Article information
  • International Journal of Cancer Management: April 2018, 11 (4); e11351
  • Published Online: April 30, 2018
  • Article Type: Research Article
  • Received: March 13, 2017
  • Revised: July 5, 2017
  • Accepted: April 16, 2018
  • DOI: 10.5812/ijcm.11351

To Cite: Abderrahmane R, Benseddik K, Louhibi L, Zohra Moghtit F, Boubekeur A, et al. Basal Cell Carcinoma Risk and TP53 Arg72Pro Polymorphism: An Algerian Population Study, Int J Cancer Manag. 2018 ; 11(4):e11351. doi: 10.5812/ijcm.11351.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705. doi: 10.1136/bmj.38219.515266.AE. [PubMed: 15364703]. [PubMed Central: PMC518891].
  • 2. Jackson BA. Nonmelanoma skin cancer in persons of color. Semin Cutan Med Surg. 2009;28(2):93-5. doi: 10.1016/j.sder.2009.04.010. [PubMed: 19608059].
  • 3. Welsh MM, Karagas MR, Applebaum KM, Spencer SK, Perry AE, Nelson HH. A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis. 2008;29(10):1950-4. doi: 10.1093/carcin/bgn160. [PubMed: 18641401]. [PubMed Central: PMC2556967].
  • 4. Basset-Seguin N, Moles JP, Mils V, Dereure O, Guilhou JJ. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol. 1994;103(5 Suppl):102S-6S. [PubMed: 7963669].
  • 5. Sherr CJ. Principles of tumor suppression. Cell. 2004;116(2):235-46. [PubMed: 14744434].
  • 6. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458(7242):1127-30. doi: 10.1038/nature07986. [PubMed: 19407794]. [PubMed Central: PMC2814168].
  • 7. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107. doi: 10.1038/nrc2584. [PubMed: 19165225].
  • 8. Dumont P, Leu JI, Della Pietra A3, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357-65. doi: 10.1038/ng1093. [PubMed: 12567188].
  • 9. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092-100. [PubMed: 9891044]. [PubMed Central: PMC116039].
  • 10. Stefanaki I, Stratigos AJ, Dimisianos G, Nikolaou V, Papadopoulos O, Polydorou D, et al. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol. 2007;156(2):357-62. doi: 10.1111/j.1365-2133.2006.07645.x. [PubMed: 17223878].
  • 11. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res. 2009;15(7):2406-16. doi: 10.1158/1078-0432.CCR-08-1719. [PubMed: 19339276]. [PubMed Central: PMC3635077].
  • 12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. [PubMed: 3344216]. [PubMed Central: PMC334765].
  • 13. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 1988;16(22):10881-90. [PubMed: 2849754]. [PubMed Central: PMC338945].
  • 14. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7(2):961-3. [PubMed: 3547088]. [PubMed Central: PMC365159].
  • 15. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003;1010:764-70. [PubMed: 15033824].
  • 16. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999;354(9174):218-9. doi: 10.1016/S0140-6736(99)01914-5. [PubMed: 10421306].
  • 17. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004;210(2):197-203. doi: 10.1016/j.canlet.2004.03.031. [PubMed: 15183535].
  • 18. Pegoraro R, Moodley J, Naiker S, Lanning P, Rom L. The p53 codon 72 polymorphism in black South African women and the risk of cervical cancer. BJOG. 2000;107(9):1164-5. [PubMed: 11002963].
  • 19. Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, et al. TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology. 2009;77(5):328-34. doi: 10.1159/000260905. [PubMed: 19940524].
  • 20. Peixoto Guimaraes D, Hsin Lu S, Snijders P, Wilmotte R, Herrero R, Lenoir G, et al. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett. 2001;162(2):231-5. [PubMed: 11146230].
  • 21. Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun. 2000;3(2):111-4. doi: 10.1006/mcbr.2000.0196. [PubMed: 10775508].
  • 22. Bendesky A, Rosales A, Salazar AM, Sordo M, Peniche J, Ostrosky-Wegman P. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res. 2007;619(1-2):38-44. doi: 10.1016/j.mrfmmm.2007.01.001. [PubMed: 17403527].
  • 23. Jiang DK, Wang WZ, Ren WH, Yao L, Peng B, Yu L. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011;131(1):220-8. doi: 10.1038/jid.2010.270. [PubMed: 20861852].
  • 24. Ramos J, Villa J, Ruiz A, Armstrong R, Matta J. UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2006-11. [PubMed: 15598755].
  • 25. Benjamin CL, Ananthaswamy HN. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol. 2007;224(3):241-8. doi: 10.1016/j.taap.2006.12.006. [PubMed: 17270229]. [PubMed Central: PMC2080850].
  • 26. Benjamin CL, Melnikova VO, Ananthaswamy HN. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:265-82. doi: 10.1007/978-0-387-77574-6_21. [PubMed: 18348463].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments